Ruxolitinib IR

DRUG2 trials

Sponsors

Incyte Corporation

Conditions

Healthy Participants

Phase 1

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

CompletedNCT06310304

Incyte CorporationHealthy Participants

Start: 2024-03-26End: 2024-05-15Updated: 2024-06-05

A Study to Evaluate the Bioequivalence of Ruxolitinib Extended Release (XR) Tablets With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants

CompletedNCT06555081

Incyte CorporationHealthy Participants

Start: 2024-09-25End: 2024-11-07Updated: 2025-02-13